Research Article

Treatment Outcome and Associated Factors among Tuberculosis Patients in Debre Tabor, Northwestern Ethiopia: A Retrospective Study

Addisu Melese, 1 Balew Zeleke, 2 and Biniam Ewnete 3

1 Department of Medical Laboratory Science, College of Health Sciences, Debre Tabor University, P.O. Box 272, Debre Tabor, Ethiopia
2 Department of Nursing, College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia
3 Department of Medicine, College of Health Sciences, Debre Tabor University, P.O. Box 272, Debre Tabor, Ethiopia

Correspondence should be addressed to Addisu Melese; addisum22@gmail.com

Received 10 March 2016; Accepted 17 July 2016

Academic Editor: Alexander S. Apt

Copyright © 2016 Addisu Melese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Assessing the outcomes of tuberculosis (TB) treatment is an important indicator for evaluation of the effectiveness of tuberculosis control programs. In Ethiopia, directly observed treatment short course (DOTS) was included in the national tuberculosis control program as a strategy but little is known about its effectiveness in the study area. Therefore, this study was aimed at assessing the treatment outcomes of TB patients and associated factors in Debre Tabor, northwest Ethiopia. Methods. A retrospective study was conducted among TB patients for the period from May 2008 to April 2013 at Debre Tabor Health Center, northwest Ethiopia. Data were entered and analyzed using SPSS version 20.0. Descriptive statistics were used to generate frequency tables and figures. Logistic regressions were used to identify factors associated with treatment outcomes at $P \leq 0.05$. Results. Out of 339 patients (197 males and 142 females) registered for antituberculosis treatment in Debre Tabor Health Center, only 303 patients were included in the treatment outcome analysis and 87.1% had successful treatment outcome while 12.9% had unsuccessful treatment outcome. In the multivariate logistic regression analysis, the odds of successful treatment outcome were higher among patients $\geq 45$ years of age (AOR = 3.807, 95% CI: 1.155–12.544) and lower among females (AOR = 0.347, 95% CI: 0.132–0.917), rural residents (AOR = 0.342, 95% CI: 0.118–0.986), and negative smear result at the second month of treatment (AOR = 0.056, 95% CI: 0.005–0.577) as compared to their counterparts. Conclusion. The treatment outcome of all forms of tuberculosis patients in Debre Tabor health center was satisfactory as expected from effective implementation of DOTS. Although the observed successful treatment outcome was in agreement with the national target, follow-up of patients during the course of treatment to trace the treatment outcomes of transferred-out patients and assessment of other potential sociodemographic factors that could affect the treatment outcomes of TB patients were also recommended.

1. Introduction

Tuberculosis has long been recognized as a major public health problem and leading cause of death alongside with HIV/AIDS [1]. Since then, control efforts including directly observed treatment short course (DOTS) have been initiated by WHO as a strategy [2]. After its launch, DOTS was recommended by international tuberculosis authorities. DOTS has shown to be effective in achieving a high successful treatment outcome [3] and became an important indicator to evaluate the effectiveness of tuberculosis control programs [4].

Early diagnosis and appropriate treatment of TB are among the cornerstones of the DOTS strategy being implemented globally. The targets to control the global epidemic, as recognized by the WHO/Stop TB Partnership and included in the Millennium Development Goals (MDGs), are to diagnose at least 70% of infectious cases and successfully treat at least 85% of them [2].

TB fueled by HIV/AIDS epidemic still remained a major health problem in Ethiopia [5]. According to the 2010/11 national population based survey of Ethiopia, the prevalence of all forms of TB was 224 per 100,000 population [6]. With
this prevalence, Ethiopia ranked 7th among the 22 high TB burden countries. In response to this burden, Ethiopia has adopted DOTS as a strategy for TB prevention and control program in the early 1990s [5]. Although DOTS has been estimated to have 100% geographical coverage, it is found only at 95% at health facilities [7].

Studies conducted in southern Ethiopia indicated that DOTS improved the treatment outcomes of tuberculosis and service coverage [8], hence preventing new infections and emergence of drug resistance, but, in Debre Tabor, even though DOTS has been implemented two decades before, the outcomes of treatment and associated factors were not yet assessed. Therefore, this study was aimed to assess the treatment outcomes and associated factors among tuberculosis patients in Debre Tabor, northwest Ethiopia, for the period covering from May 2008 to April 2013.

2. Methods

2.1. Study Design and Setting. A retrospective study was employed to assess the treatment outcome and associated factors among all forms of TB patients in Debre Tabor. Debre Tabor is a zonal town, 667 kilometers away from the capital, Addis Ababa. The health service delivering institutions are comprised of one general hospital, three health centers, and two private clinics during data collection. Debre Tabor Health Center was randomly selected for this study. Health centers are primary healthcare units capable of serving 15,000–25,000 population.

2.2. Data Collection. Data were collected by nurses using a structured sheet specially designed for this study. Patients diagnosed for TB were transferred to DOTS clinic and started treatment according to the national guideline. Patient data on age, sex, residence, type of TB, smear results at baseline and 2nd, 5th, and 7th months, HIV status, year of treatment, patient category during the start of treatment, and the outcomes of treatment were extracted from Debre Tabor Health Center, DOTS clinic.

2.3. Inclusion and Exclusion Criteria. Patients diagnosed for any form of TB and started treatment from May 2008 to April 2013 were included while patients under treatment and with incomplete sociodemographic information were excluded.

2.4. Laboratory Diagnosis of TB. In Debre Tabor Health Center, pulmonary TB was diagnosed using suggestive clinical signs and symptoms in combination with Ziehl-Neelsen staining and/or chest X-ray. Spot-morning-spot sputum was the specimen used to diagnose PTB. EPTB was diagnosed using clinical information supported with radiography, ultrasound, and cytology and/or pathological procedures through patient referral system with nearby hospitals (Debre Tabor, Felege Hiwot, Gondar) and private clinics.

2.5. Laboratory Diagnosis of HIV. For the screening of HIV, the nationally recognized test algorithm was employed in the health center according to the manufacturer’s instructions and HIV results were obtained from patient registers. KHB (Shanghai Kehua Bio-Engineering Co., Ltd., China) was used as screening and positive test results were repeated with STAT-PACK (Chembio HIV-1/2 STATPAK™ Assay, CHEMBIO DIAGNOSTIC SYSTEMS, Inc., Medford, NY, USA). Discordant results from KHB and STAT-PACK were defined by the tie-breaker (UNI-GOLD, HIV, Trinity Biotech PLC, Co., Wicklow, Ireland).

2.6. Data Analysis. Data were entered and analyzed using Statistical Package for Social Sciences (SPSS) Version 20.0 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp., 2011). Descriptive statistics were used to generate and summarize frequencies. Bivariate and multivariate logistic regressions were used to assess the relationship between treatment outcome and independent variables.

3. Case and Treatment Outcome Definitions

3.1. Patient Category

New Case. It is a patient who has never had treatment for TB before or has been on anti-TB treatment less than four weeks.

Relapse. It is a patient who has been declared cured or has completed treatment of any form of TB in the past but who reports back and was found to be smear positive.

Treatment Failure. It is a patient who while on treatment remained smear positive or became again smear positive at the end of the five months or later, after commencing treatment.

Default. It is a patient who had previously registered as defaulted from treatment and returns to the health facility and found to be smear positive sputum.

Transfer In. It is a patient who started treatment in one health facility (reporting unit) and transferred to another health facility (receiving unit) to continue treatment.

Unknown. It is a patient whose category at the start of treatment was not mentioned or neither of the above.

3.2. Type of TB

Smear Positive Pulmonary TB. It is a patient with at least two sputum specimens positive for AFB by microscopy or one positive sputum specimen for AFB by microscopy and a positive culture or a patient with one positive sputum specimen by microscopy and abnormal chest X-ray indicative of active TB as decided by a clinician.

Smear Negative Pulmonary TB. It is a patient with symptoms that are suggestive of TB with three negative sputum smear results by direct microscopy and that do not respond to courses of broad-spectrum antibiotics or three negative
sputum smear results by direct microscopy and radiographic abnormalities indicative for pulmonary TB or a patient with three negative sputum smear results by direct microscopy and positive sputum culture for MTB.

**Extrapulmonary TB (EPTB).** It is tuberculosis of organs/tissues other than lungs proven by culture, histopathology, and symptoms suggestive of active extrapulmonary TB and decisions made by clinicians to treat with anti-TB drugs. Sputum examination and chest radiographs were used to evaluate the involvement of lungs.

3.3. Treatment Outcome

**Cured.** They are patients who completed treatment with negative bacteriology result at the end of treatment.

**Completed.** They are patients who finished treatment, but without bacteriology result at the end of treatment.

**Failure.** They are patients who remained smear positive at five months/later despite correct intake of medication.

**Defaulted.** They are patients who interrupted their treatment after registration for treatment.

**Died.** They are patients who died from any cause during the course of treatment.

**Transferred Out.** They are patients in whom information on treatment outcome cannot be obtained due to transfer to another health facility.

**Successful Treatment.** It is a patient who was cured or has completed treatment.

**Treatment Success Rate (TSR).** It is the sum of the percentages of cured and patients who completed treatment.

4. Results

4.1. Sociodemographic Characteristics of Patients. Out of 339 TB patients included in this study, 197 (58.1%) were males and 142 (41.9%) were females. Majority (60.8%) of the patients were urban residents. Most cases reported were from 25 to 44 years of age. The mean age and standard deviation (SD) of the patients were 34.9 ± 17.4 (range 1–78) years (Table 1).

4.2. Category of Patients. Among TB patients at the start of treatment, 89.1% were new cases, 3.8% were relapsed, 0.6% were failed, 5.3% were transferred in, and 1.2% were unknown cases. Based on the type of TB, 38.9% of the patients were diagnosed as EPTB, 33.3% smear negative PTB, and 27.7% smear positive PTB. Females, patients ≤ 14 years of age, and new TB patients had higher rate of EPTB than smear negative and smear positive PTB. HIV test was done for 71.68% of patients and 12.7% were positive. The rate of TB-HIV coinfection was 16.28% among smear positive PTB, 32.56% among smear negative PTB, and 51.16% among EPTB (Table 2).

Table 1: Characteristics of TB patients (N = 339), Debre Tabor Health Center, 2008–2013.

| Characteristics | Frequency | Percentage |
|-----------------|-----------|------------|
| Sex             |           |            |
| Male            | 197       | 58.1       |
| Female          | 142       | 41.9       |
| Residence       |           |            |
| Urban           | 206       | 60.8       |
| Rural           | 133       | 39.2       |
| Age             |           |            |
| ≤24             | 102       | 30.1       |
| 25–44           | 140       | 41.3       |
| ≥45             | 97        | 28.6       |
| HIV status      |           |            |
| Positive        | 43        | 12.7       |
| Negative        | 200       | 59.0       |
| Unknown         | 96        | 28.3       |
| Patient category|           |            |
| New             | 302       | 89.1       |
| Relapse         | 13        | 3.8        |
| Failure         | 2         | 0.6        |
| Transfer in     | 18        | 5.3        |
| Unknown         | 4         | 1.2        |
| Baseline smear result |     |            |
| Smear positive  | 94        | 27.7       |
| Smear negative  | 285       | 72.3       |

Figure 1: Trends of types of TB over the course of five years at Debre Tabor Health Center, 2008–2013.

Over the five years, the types of TB showed a different trending pattern from one year to another as shown in Figure 1.

4.3. Treatment Outcome. Among the TB patients included in this study, 67 patients (19.8%) were cured, 197 (58.1%) completed the treatment, 12 (3.5%) failed, 8 (2.4%) defaulted,
Table 2: Patients characteristics and type of TB at Debre Tabor Health Center, 2008–2013.

| Variables       | Smear positive PTB (%) | Smear negative PTB (%) | EPTB (%) | Total (%) |
|-----------------|------------------------|------------------------|----------|-----------|
| Sex             |                        |                        |          |           |
| Male            | 55 (28.0)              | 71 (36.0)              | 71 (36.0)| 197 (58.1)|
| Female          | 39 (27.5)              | 42 (29.6)              | 61 (43.0)| 142 (41.9)|
| Residence       |                        |                        |          |           |
| Urban           | 52 (25.2)              | 70 (34)                | 84 (40.8)| 206 (60.8)|
| Rural           | 42 (31.6)              | 43 (32.3)              | 48 (36.1)| 133 (39.2)|
| Age group       |                        |                        |          |           |
| ≤24             | 24 (23.5)              | 31 (30.4)              | 47 (46.1)| 102 (30.1)|
| 25–44           | 49 (35.0)              | 42 (30.0)              | 49 (35.0)| 140 (41.3)|
| ≥45             | 21 (21.6)              | 40 (41.2)              | 36 (37.1)| 97 (28.6) |
| HIV status      |                        |                        |          |           |
| Positive        | 7 (16.3)               | 14 (32.6)              | 22 (51.2)| 43 (12.7) |
| Negative        | 60 (30.0)              | 63 (31.5)              | 77 (38.5)| 200 (59.0)|
| Unknown         | 27 (28.1)              | 36 (37.5)              | 33 (34.4)| 96 (28.3) |
| Patient category|                        |                        |          |           |
| New             | 80 (26.5)              | 101 (33.4)             | 121 (40.1)| 302 (89.1)|
| Relapse         | 11 (84.6)              | 2 (15.4)               | 0 (00.0) | 13 (3.8)  |
| Failure         | 2 (100%)               | 0 (00.0)               | 0 (00.0) | 2 (0.6)   |
| Transferred in  | 1 (5.6)                | 9 (50.0)               | 8 (44.4) | 18 (5.3)  |
| Unknown         | 0 (00.0)               | 1 (25.0)               | 3 (75.0) | 4 (1.2)   |
| Total           | 94 (27.7)              | 113 (33.3)             | 132 (38.9)| 339 (100) |

Figure 2: Trends of treatment outcomes of TB over the course of five years at Debre Tabor Health Center.

19 (5.6%) died, and 36 (10.6%) patients were transferred out (transferred to another health facility). The rate of cure among all forms TB cases was 19.8% while the rate of treatment completion was 58.1%. The rate of treatment failure, default, and death was 3.5%, 2.4%, and 5.6%, respectively. As age of the patient increased, the trend of completing treatment showed a decreasing pattern while death rate showed an increasing pattern (Table 3).

The trend of transferred-out TB patients has showed a similar pattern while other treatment outcomes had different trends over the course of five years (Figure 2).

Logistic regression was employed to assess sociodemographic variables including age, sex, place of residence, HIV status, baseline smear result, smear result at the 2nd, 5th, and 7th months of treatment, type of TB, year of treatment, and patient category at start of treatment. In the multivariate analysis, the treatment outcome was varied with age, sex, place of resident, and smear result at 2nd month and year of treatment. The odds of successful treatment outcome was 3.807 (95% CI: 1.155–12.544) times higher among patients older than 45 years of age compared to patients younger than 14 years and 25–44 years of age. Females had lower rates of successful treatment (AOR: 0.347, 95% CI: 0.132–0.917).

Patients were less likely to have successful treatment if they were rural residents (AOR: 0.342, 95% CI: 0.118–0.986) compared to urban residents. Successful treatment outcome
was less frequent (AOR: 0.056, 95% CI: 0.005–0.577) among smear negative patients than smear positive patients at the 2nd month of treatment.

## 5. Discussion

Evaluation of the treatment outcome and associated factors for TB patients has the greatest importance in assessing the effectiveness of DOTS program in a country (Table 4). Since the treatment outcome of transferred-out cases was unknown, they were excluded from the final evaluation. Of the 303 patients assessed for their treatment outcomes at Debre Tabor Health Center under DOTS clinic, 264 (87.1%) had successful treatment outcome. This overall treatment success rate for all cases of tuberculosis in our study was supported by various studies conducted in Ethiopia with success rates of 86.2% in northeastern Ethiopia [9] and 85% at Kola Diba [10] while it was higher than studies conducted at Felege Hiwot Referral Hospital (26%) [11], in southern region (49.5%) [8], in Addis Ababa (82.7%) [12], and lower than studies conducted at Enfranz (94.8%) [13]. This satisfactory treatment success rate might be attributable to relatively lower transferred-out rates (10.62%), failures (3.5%), default rate (2.4%), and death rate (5.6%).

Our study revealed that males were more likely to default, to fail, to die, and to transfer out than females and this was consistent with a study conducted in southern Ethiopia [14]. Literatures showed that poor treatment outcomes are associated with inadequate treatment adherence. A study conducted somewhere else in Ethiopia reported that patient behavior and attitude about the disease are major factors affecting adherence to TB treatment [15]. The higher social interaction outside home by males, social isolation associated with TB leading to treatment rejection, alcoholism, and other related behaviors among males might contribute to their higher default, failure, death, and transfer-out rates.

From May 2008 to April 2011, the trends of smear negative PTB showed an increasing pattern while it showed an increasing trend in later years. Smear negative PTB patients had high treatment success rates compared to EPTB and smear positive PTB patients with treatment success rate of 89.5%, 87.2%, and 84.0%, respectively. The treatment success of smear positive pulmonary TB patients in this study was slightly lower than the 87% WHO international target, 89.0% in Tigray region [16], and 89.3% in the southern region of Ethiopia [17] but higher than studies conducted in Ethiopia including 72.2% in Gambela region [18], 74.8% in southern region [14], and 29.5% in Gondar [3].
Table 4: Factors associated with treatment outcome of TB patients in Debre Tabor, 2008–2013, N = 303.

| Variables                  | Treatment outcome | COR (95% CI) | P value | AOR (95% CI) | P value |
|----------------------------|-------------------|--------------|---------|--------------|---------|
|                            | Successful (%)    | Unsuccessful (%) |         |              |         |
| Sex                        |                   |              |         |              |         |
| Male                       | 144 (83.2)        | 29 (16.8)    | 1.00    | 1.00         |         |
| Female                     | 120 (92.3)        | 10 (7.7)     | 0.414 (0.194–0.883) | 0.023   | 0.347 (0.132–0.917) | 0.033 |
| Residence                  |                   |              |         |              |         |
| Urban                      | 158 (85.0)        | 29 (15.0)    | 1.00    | 1.00         |         |
| Rural                      | 106 (84.1)        | 10 (7.9)     | 0.514 (0.240–1.099) | 0.086   | 0.342 (0.118–0.986) | 0.047 |
| Age in groups              |                   |              |         |              |         |
| ≤24                        | 80 (90.9)         | 8 (9.1)      | 1.00    | 1.00         |         |
| 25–44                      | 118 (90.8)        | 12 (9.2)     | 1.017 (0.398–2.600) | 0.972   | 1.041 (0.298–3.634) | 0.949 |
| ≥45                        | 66 (77.6)         | 19 (22.4)    | 2.879 (1.185–6.996) | 0.020   | 3.807 (1.155–12.544) | 0.028 |
| Type of TB                 |                   |              |         |              |         |
| Smear positive PTB         | 68 (84.0)         | 13 (16.0)    | 1.00    | 1.00         |         |
| Smear negative PTB         | 94 (89.5)         | 11 (10.5)    | 0.612 (0.259–1.449) | 0.264   | 0.240 (0.034–1.724) | 0.156 |
| Extrapulmonary TB          | 102 (87.2)        | 15 (12.8)    | 0.796 (0.344–1.718) | 0.522   | 0.355 (0.049–2.603) | 0.308 |
| HIV status                 |                   |              |         |              |         |
| Negative                   | 160 (89.4)        | 19 (10.6)    | 1.00    | 1.00         |         |
| Positive                   | 35 (85.4)         | 6 (14.6)     | 1.444 (0.537–3.877) | 0.466   | 1.155 (0.322–4.146) | 0.825 |
| Unknown                    | 69 (83.1)         | 14 (16.9)    | 1.709 (0.810–3.602) | 0.159   | 1.558 (0.312–7.769) | 0.589 |
| Patient category           |                   |              |         |              |         |
| New                        | 234 (87.6)        | 33 (12.4)    | 1.00    | 1.00         |         |
| Relapse                    | 8 (61.5)          | 5 (38.5)     | 4.432 (1.368–14.355) | 0.013   | 3.906 (0.470–32.483) | 0.207 |
| Failure                    | 1 (50.0)          | 1 (50.0)     | 7.091 (0.433–116.103) | 0.170   |                   |       |
| Transferred in             | 17 (100.0)        | 0 (0.0)      |         |              |         |
| Unknown                    | 4 (100.0)         | 0 (0.0)      |         |              |         |
| Baseline smear result      |                   |              |         |              |         |
| Smear positive             | 68 (84.0)         | 13 (16.0)    | 1.00    | 1.00         |         |
| Smear negative             | 196 (88.3)        | 26 (12.9)    | 0.694 (0.338–1.426) | 0.320   | 0.460 (0.071–2.963) | 0.414 |
| Smear result at 2nd month  |                   |              |         |              |         |
| Positive                   | 3 (30.0)          | 7 (70.0)     | 1.00    | 1.00         |         |
| Negative                   | 63 (94.0)         | 4 (6.0)      | 0.027 (0.005–0.147) | 0.000   | 0.056 (0.005–0.577) | 0.015 |
| Not done                   | 198 (87.6)        | 28 (12.4)    | 0.061 (0.015–0.248) | 0.000   | 0.140 (0.004–5.559) | 0.296 |
| Year of treatment          |                   |              |         |              |         |
| May 2008–April 2009        | 55 (83.3)         | 11 (16.7)    | 2.850 (0.856–9.489) | 0.088   | 2.726 (0.319–23.266) | 0.359 |
| May 2009–April 2010        | 55 (80.9)         | 13 (19.1)    | 3.368 (1.035–10.965) | 0.044   | 3.650 (0.806–16.522) | 0.093 |
| May 2010–April 2011        | 43 (87.8)         | 6 (12.2)     | 1.988 (0.528–7.485) | 0.310   | 3.624 (0.701–18.727) | 0.124 |
| May 2011–April 2012        | 54 (91.5)         | 5 (8.5)      | 1.319 (0.336–5.174) | 0.691   | 1.637 (0.302–8.880) | 0.568 |
| May 2012–April 2013        | 57 (93.4)         | 4 (6.6)      | 1.00    | 1.00         |         |
| Total                      | 264 (87.1)        | 39 (12.9)    |         |              |         |

The relatively lower overall successful treatment outcome of smear positive PTB in our study when compared to WHO target and other studies conducted in Ethiopia could be attributed to poor smear microscopy resulting in false smear negative PTB. Another possible reason for the relatively lower successful treatment outcome could be lack of tracing out of the treatment outcomes of defaulted patients.

The overall TB-HIV coinfection rate at Debre Tabor Health Center was 12.7%. This figure was lower than previous studies conducted at Gondar University Hospital and north-eastern parts of Ethiopia showing high proportions (52.1% and 24.3%, resp.) of coinfection [9, 19]. The lower rate in this study might be explained in terms of unavailability of HIV counseling and testing services in earlier years in the study area or refusal of patients to be tested for HIV (83 patients were registered with their HIV status unknown).

Majority of study participants showing TB-HIV coinfection were those with EPTB (51.2%) followed by smear negative pulmonary (32.6%) and the least coinfection was reported among smear positive pulmonary TB patients (16.3%). The rate of occurrence of TB-HIV coinfection among EPTB patients was three times higher than smear...
positive pulmonary patients and 1.5 times higher than smear negative PTB. This finding was in agreement with studies conducted in Ethiopia and India [19–21] and evidenced by other literatures as EPTB and smear negative PTB are HIV associated infections.

Contrary to our findings, studies conducted in northeastern part of Ethiopia showed that TB-HIV co-infection was higher among smear positive PTB than smear negative PTB and EPTB [9]. Smear positive PTB and HIV positive patients had experienced higher rate of treatment failure than their counterparts. HIV status, baseline smear result, smear result at the 5th and 7th months of treatment, type of TB, year of treatment, and patient category at start of treatment had no significant association with treatment outcome.

This study also compared the treatment success rates at Debre Tabor Health Center with the national success rates. To this end, there was a relatively similar treatment success rate among patients in Debre Tabor Health Center compared to the national treatment success rates (83.3% versus 84% and 80.9% versus 84%, resp.) in the first two years of treatment while relatively higher success rates were observed in the last three years of treatment (87.8% versus 83%, 91.5% versus 86% and 93.4% versus 91%), respectively (Table 5).

### Table 5: Comparison of TSR in Debre Tabor with the national TSR, 2008–2013, N = 303.

| Year of treatments       | Treatment success | TSR in DTHC | National TSR |
|--------------------------|-------------------|-------------|--------------|
|                          | Success (N)       | Unsuccessful (N) |              |
| May 2008–April 2009      | 55                | 11          | 83.3         | 84<sup>a</sup> |
| May 2009–April 2010      | 55                | 13          | 80.9         | 84<sup>b</sup> |
| May 2010–April 2011      | 43                | 6           | 87.8         | 83<sup>c</sup> |
| May 2011–April 2012      | 54                | 5           | 91.5         | 86<sup>d</sup> |
| May 2012–April 2013      | 57                | 4           | 93.4         | 91<sup>e</sup> |
| Total                    | 264               | 39          | 87.1         |              |

<sup>a</sup>: WHO 2010, <sup>b</sup>: WHO 11, <sup>c</sup>: WHO 2012, <sup>d</sup>: WHO 2013, and <sup>e</sup>: WHO 2014.

6. Conclusion

The treatment outcome of all forms of tuberculosis patients in Debre Tabor was satisfactory as expected from effective implementation of DOTS. Although the observed successful treatment outcome was in agreement with the national target, follow-up of patients during the course of treatment to trace the treatment outcomes of transferred out patients and assessment of other potential sociodemographic factors that could affect the treatment outcomes of TB patients were also recommended.

### Additional Points

**Limitations of the Study.** Patient registration books reviewed lacked data about the HIV status of all TB patients for the year 2008/2009 and few patients for the year 2009/2010 in which patients HIV status was not reported. This will affect the TB-HIV coinfection rate and their treatment outcomes. The retrospective nature of the study could not identify sociodemographic factors that could affect the treatment outcomes of patients that were not included during registration of patients for treatment.

### Ethical Approval

Ethical clearance was obtained from Ethical Review Committee of College of Medicine and Health Science, Bahir Dar University, and the Amhara Regional Health Bureau. Letter of permission was given to South Gondar zone health department and Debre Tabor town health office. Permission was also sought from Debre Tabor Health Center to access patient data. To ensure confidentiality, patient identifiers were not included and data were used only for the intended study.

### Competing Interests

The authors declare that they have no competing interest.

### Authors’ Contributions

Addisu Melese conceived and designed the study, participated in data collection, entered and analyze data, interpreted the results, and drafted the paper. Balew Zeleke participated in the design, data collection, and analysis. Biniam Ewnete participated in data collection and interpretation. All authors reviewed and approved final drafts of the paper.

### Acknowledgments

The authors would like to thank staff of Debre Tabor Health Center, DOTS clinic, for their unreserved cooperation throughout the course of data collection.

### References

[1] World Health Organization (WHO), Global Tuberculosis Report, 2015.

[2] World Health Organization (WHO), “Global tuberculosis control: surveillance, planning and financing,” WHO Report WHO/HTM/TB/2008.393, WHO, Geneva, Switzerland, 2008.

[3] B. Tessa, A. Muche, A. Bekele, D. Reissig, F. Emmrich, and U. Sack, “Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five-year retrospective study,” BMC Public Health, vol. 9, article 371, 2009.
B. Tessema, J. Beer, F. Emmrich, U. Sack, and A. C. Rodloff, “Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia,” *BMC Infectious Diseases*, vol. 12, article 37, 2012.

Ministry of Health of Ethiopia (MOH), *Guidelines for Clinical and Programmatic Management of TB, TB/HIV and Leprosy*, 5th edition, 2013.

Z. Alebachew, A. Kebede, F. Tsegaye et al., *First Ethiopian National Population Based Tuberculosis Prevalence Survey*, July 2011.

Federal Ministry of Health: overview of national TB control implementation status,” in *Proceedings of the 6th National TB Research Workshop*, vol. 2011, Gondar University, Gondar, Ethiopia, June 2011.

E. B. Shargie and B. Lindtjørn, “DOTS improves treatment outcomes and service coverage for tuberculosis in South Ethiopia: a retrospective trend analysis,” *BMC Public Health*, vol. 5, article 62, 2005.

D. Mekonnen, A. Derbie, and E. Desalegn, “TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study,” *BMC Research Notes*, vol. 8, no. 1, article 666, 2015.

M. G. Beza, M. T. Wubie, M. D. Teferi et al., “A five years tuberculosis treatment outcome at kolla diba health center, dembia district, northwest ethiopia: a retrospective cross-sectional analysis,” *Journal of Infectious Diseases and Therapy*, vol. 1, article 101, 2013.

F. Biadglegne, B. Anagaw, T. Debebe et al., “A retrospective study on the outcomes of tuberculosis treatment in Felege Hiwot referral hospital, Northwest Ethiopia,” *International Journal of Medicine and Medical Sciences*, vol. 5, no. 2, pp. 85–91, 2013.

B. Getahun, G. Ameni, G. Medhin, and S. Biadgilign, “Treatment outcome of tuberculosis patients under directly observed treatment in Addis Ababa, Ethiopia,” *Brazilian Journal of Infectious Diseases*, vol. 17, no. 5, pp. 521–528, 2013.

M. Endris, F. Moses, Y. Belyhun, E. Woldehana, A. Esmael, and C. Unakal, “Treatment outcome of tuberculosis patients at enfraz health center, Northwest Ethiopia: a five-year retrospective study,” *Tuberculosis Research and Treatment*, vol. 2014, Article ID 72693, 7 pages, 2014.

M. Muñoz-Sellart, L. E. Cuevas, M. Tumato, Y. Merid, and M. A. Yassin, “Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia,” *International Journal of Tuberculosis and Lung Disease*, vol. 14, no. 8, pp. 973–979, 2010.

M. Gelaw, T. Genebo, A. Dejene, E. Lemma, and G. Eyob, “Attitude and social consequences of tuberculosis in Addis Ababa, Ethiopia,” *East African Medical Journal*, vol. 78, no. 7, pp. 382–388, 2001.

G. Berhe, F. Enqueselassie, and A. Aseffa, “Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia,” *BMC Public Health*, vol. 12, no. 1, article 537, 2012.

D. G. Dattiko and B. Lindtjørn, “Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial,” *PLoS ONE*, vol. 4, no. 5, Article ID e5443, 2009.

D. Demeke, M. Legesse, and J. Bati, “Trend of tuberculosis and treatment outcomes in gambella region with special emphasize on gambella regional hospital, Western Ethiopia,” *Mycobacterial Diseases*, vol. 3, article 180, 2013.

A. Kassu, G. Mengistu, B. Ayele et al., “Coinfection and clinical manifestations of tuberculosis in human immunodeficiency virus-infected and -uninfected adults at a teaching hospital, Northwest Ethiopia,” *Journal of Microbiology, Immunology and Infection*, vol. 40, no. 2, pp. 116–122, 2007.

A. Gellete, D. Kebede, and Y. Berhane, “Tuberculosis and HIV infection in Southern Ethiopia,” *The Ethiopian Journal of Health Development*, vol. 11, pp. 51–59, 1997.

S. K. Sharma and A. Mohan, “Extrapulmonary tuberculosis,” *Indian Journal of Medical Research*, vol. 120, no. 4, pp. 316–353, 2004.